Jasper Therapeutics, Inc.
جودة البيانات: 83%
KWD 0.80
▼
KWD 0.02
(-2.59%)
القيمة السوقية: 23.06 M
السعر
KWD 0.82
القيمة السوقية
23.06 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Negative free cash flow of -77.16 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-432.26%
أقل من متوسط القطاع (-53.47%)
ROIC-212.42%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio2.59
Interest CoverageN/A
التقييم
PE (TTM)
-0.30
أعلى من متوسط القطاع (-1.48)
P/B Ratio1.99
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -0.3 | -1.5 |
| P/B | 2.0 | 1.6 |
| ROE % | -432.3 | -53.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
5 محللين
Buy
الحالي
KWD 0.80
المستهدف
KWD 7.70
KWD 1.50
KWD 6.00
KWD 20.00
التوقعات
مكرر الربحية المستقبلي
-0.48
ربحية السهم المستقبلية
-KWD 1.67
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.67
-KWD 2.56 – -KWD 1.14
|
0.0 | 3 |
| FY2026 |
-KWD 2.44
-KWD 3.29 – -KWD 1.34
|
0.0 | 4 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.55
-KWD 0.55 – -KWD 0.55
|
0.0 | 1 |
| 2026 Q1 |
-KWD 0.54
-KWD 0.54 – -KWD 0.54
|
0.0 | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.82 | -KWD 0.54 | +33.8% |
| Q32025 | -KWD 1.29 | -KWD 1.25 | +3.1% |
| Q22025 | -KWD 1.33 | -KWD 1.74 | -31.2% |
| Q12025 | -KWD 1.48 | -KWD 1.41 | +4.5% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -75.80 M |
| ROE | -432.26% | ROA | -145.86% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -77.16 M |
| ROIC | -212.42% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2.59 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 33.52 M | Tangible Book Value | 11.57 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.30 | Forward P/E | N/A |
| P/B Ratio | 1.99 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -334.64% | ||
| Market Cap | 23.06 M | Enterprise Value | -27.84 M |
| Per Share | |||
| EPS (Diluted TTM) | -3.95 | Revenue / Share | N/A |
| FCF / Share | -2.76 | OCF / Share | -2.76 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 101.79% |
| SBC-Adj. FCF | -84.21 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -75.80 M | -71.27 M | -64.47 M | -37.69 M | -30.64 M |
| EPS (Diluted) | -3.95 | -4.89 | -6.18 | -1.03 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -83.88 M | -76.24 M | -68.86 M | -51.20 M | -36.83 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 63.10 M | 55.82 M | 51.79 M | 34.63 M | 25.42 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 1.06 M | 1.37 M | 1.11 M | 975,000.0 | 377,000.0 |
| Interest Expense | — | — | -246,000.0 | — | -80,000.0 |
| Income Tax | 2,000.0 | 2,000.0 | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 35.78 M | 79.90 M | 94.89 M | 48.36 M | 93.65 M |
| Total Liabilities | 31.63 M | 18.23 M | 16.45 M | 12.37 M | 24.14 M |
| Shareholders' Equity | 4.15 M | 61.67 M | 78.44 M | 35.99 M | 69.52 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 28.69 M | 71.64 M | 86.89 M | 38.25 M | 84.70 M |
| Current Assets | 34.65 M | 75.81 M | 88.94 M | 41.73 M | 87.83 M |
| Current Liabilities | 13.20 M | 15.24 M | 12.37 M | 7.07 M | 8.02 M |
{"event":"ticker_viewed","properties":{"ticker":"JSPR","listing_kind":"stock","pathname":"/stocks/jspr","exchange":"Nasdaq","country":"US"}}
